Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02114


Purpose:

The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.


Criteria:

Inclusion Criteria: - Ability to provide written informed consent and comply with study assessments for the full duration of the study - Age > 18 years old - Patients with superficial or deep corneal neovascularization that extends farther than 2 mm from the limbus Exclusion Criteria: - Has received investigational therapy within 60 days prior to study entry - Has received treatment with anti-VEGF agents (intraocular or systemic) within 45 days of study entry - Concurrent use of systemic anti-VEGF agents - Full thickness or lamellar keratoplasty within 90 days prior to study entry - Ocular surface reconstruction within 90 days prior to study entry - Other ocular surgeries within 90 days prior to study entry - Corneal or ocular surface infection within 90 days prior to study entry - Ocular or periocular malignancy - Contact lens (excluding bandage contact lens) within 30 days prior to study entry - Persistent epithelial defect (>1mm2 and ≥14 days duration) within 30 days prior to study entry - Systemic, intravitreal, or periocular steroids within 30 days prior to study entry - Change in dose/frequency of topical steroids and/or NSAIDs within 30 days prior to study entry - Hypertension: systolic BP > 150 or diastolic BP > 90 - History of thromboembolic event within 6 months prior to study entry - Current diagnosis of diabetes, Pregnancy (positive pregnancy test) or lactation - Premenopausal women not using adequate contraception (The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch) - Participation in another simultaneous medical investigation or trial.


NCT ID:

NCT00681889


Primary Contact:

Principal Investigator
Reza Dana, M.D., MPH
Massachusetts Eye and Ear Infirmary


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02114
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 20, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.